Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
All people who have a heart transplant are at risk for developing cardiac allograft
vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated
with poor heart transplant function. People who develop antibodies after transplant have a
higher risk of developing CAV. Infections, high cholesterol, and rejection also increase the
risk of developing CAV. People who develop CAV usually have to receive another transplant.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Clinical Trials in Organ Transplantation Genentech, Inc. National Heart, Lung, and Blood Institute (NHLBI) Rho Federal Systems Division, Inc.